The University of Florida College of Medicine – Jacksonville is the largest of the three University of Florida Health Science Center Jacksonville colleges — medicine, nursing and pharmacy. The college's 16 clinical science departments house more than 440 faculty members and 380 residents and fellows.

During the past decade, University of Florida College of Medicine conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 21 clinical trials were completed, i.e. on average, 77.8% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 13 clinical trials were completed. i.e. 108.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Florida College of Medicine" #1 sponsor was "Boehringer Ingelheim" with 9 trials, followed by "United Therapeutics" with 5 trials sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 3 trials sponsored, "Actelion" with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Florida College of Medicine" #1 collaborator was "American Lung Association" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "National Cancer Institute (NCI)" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "University of Florida College of Medicine" are "Pulmonary Arterial Hypertension" (6 trials), "Pulmonary Hypertension" (4 trials), "Lung Diseases, Interstitial" (3 trials), "Combined Pulmonary Fibrosis and Emphysema" (2 trials) and "Herpes Simplex" (2 trials). Many other conditions were trialed in "University of Florida College of Medicine" in a lesser frequency.

Most popular intervention types in "University of Florida College of Medicine" are "Drug" (32 trials), "Other" (3 trials), "Biological" (2 trials), "Combination Product" (2 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Nintedanib" (5 trials), "Acyclovir" (2 trials), "Antihemophilic Factor (Recombinant)" (2 trials) and "Inhaled Treprostinil" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Florida College of Medicine" are 39 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of Florida College of Medicine". 1 are not yet recruiting, 9 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in University of Florida College of Medicine, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in University of Florida College of Medicine, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 2 trials that are defined as “Not Applicable".